– USA, CA – Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), a commercial biopharmaceutical company, today announced the appointment of Laura Hamill to its Board of Directors, bringing more than three decades of experience in the biopharma industry.
About Laura Hamill
Before Gilead, Laura Hamill spent 18 years at Amgen Inc. in several leadership roles in the U.S. and internationally, concluding her time there as VP and General Manager, with strategic oversight of Amgen’s U.S. commercial operations. During her career, Ms. Hamill has worked across a vast array of therapeutic areas, including inflammation, oncology, pain, virology, and cardiovascular disease. She is a member of the boards of directors of BB Biotech, AnaptysBio, Inc., Pardes Biosciences, Y-mAbs Therapeutics, Inc., and Unchained Labs, a private company of Carlyle Group. Ms. Hamill also served on the board of directors at Acceleron Pharmaceuticals, Inc. before it was acquired by Merck in 2021.
“I am delighted to join the Board of Scilex. The company’s first commercial product, ZTlido is in the midst of a highly successful growth curve and I’m extremely excited to now be involved as its late-stage clinical and commercial development plans come together for a potential first to market entry into sciatica and chronic low back pain opportunity. I look forward to helping the company grow its impressive non-opioid pain footprint and help it establish a strong growth trajectory,” said Laura Hamill.
Ms. Hamill holds a B.A. in business administration from the University of Arizona.
About Scilex Holding Company
Scilex Holding Company, a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc., is dedicated to the development and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize the quality of life. Highly positive results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXATM, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain. Scilex launched its first commercial product in October 2018 and is developing its late-stage pipeline, which includes a pivotal Phase 3 candidate and one Phase 2 and one Phase 1 candidate. Its commercial product, ZTlido (lidocaine topical system) 1.8%, or ZTlido, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. Scilex’s three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA™, a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103 (lidocaine topical system) 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program expected to be initiated this year.
Scilex Holding Company is headquartered in Palo Alto, California, with operations in both Palo Alto and San Diego, California.
For more information: https://www.scilexholding.com/
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial-stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease, and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies, immuno-cellular therapies, antibody-drug conjugates, and oncolytic virus. Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC, and COVIDROPS; and diagnostic test solutions, including COVITRACK and COVISTIX.
Sorrento’s commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin, and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has been cleared for a Phase II trial for intractable pain associated with cancer and a Phase II trial in osteoarthritis patients. Positive top-line results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXATM, its novel, non-opioid product for the treatment of lumbosacral radicular pain, were announced in March 2022. ZTlido was approved by the FDA on February 28, 2018.
For more information: https://sorrentotherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
